SIGA reported Q4 product sales of USD 2.2 million, down 97%, and total revenues of USD 3.8 million, down 95%. Q4 operating loss was USD 9.5 million and net loss was USD 5.4 million. For FY 2025, product sales were USD 88 million, down 34%, and total revenues were USD 94.6 million, down 32%. FY 2025 operating income was USD 23.7 million, down 66%, while net income was USD 23.3 million, down 61%. The company said it received a USD 13 million Asia-Pacific procurement order for oral TPOXX in January, and CEO Diem Nguyen said SIGA is focused on securing new procurement contracts and orders in 2026 after generating USD 88 million in product revenues and USD 24 million in pre-tax operating income in 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SIGA Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603101601PRIMZONEFULLFEED9669392) on March 10, 2026, and is solely responsible for the information contained therein.
Comments